DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Acutaas Chemicals Limited — Outcome of Board Meeting

NSE 57 min ago·27 Oct 2026, 7:20 am

Acutaas Chemicals

Acutaas Chemicals Limited has informed the stock exchanges regarding its financial results for the period ending September 30, 2026. This announcement marks the release of the company's quarterly performance data, which includes details on its revenue, expenses, and profitability for the third quarter of the fiscal year.

For investors, this update is a key milestone as it provides the latest insight into the company's operational health and financial trajectory. It allows stakeholders to assess the company's current momentum and compare its performance against previous quarters and industry benchmarks.

Investors should focus on the specific metrics provided in the report, such as net profit margins and sales growth, to gauge the company's efficiency. Moving forward, market participants will watch for management commentary on future outlook and any guidance provided regarding upcoming quarters.